Medipharm Labs Corp (LABS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medipharm Labs Corp (LABS) has a cash flow conversion efficiency ratio of -0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-778.00K ≈ $-562.79K USD) by net assets (CA$35.10 Million ≈ $25.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LABS cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Medipharm Labs Corp - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Medipharm Labs Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medipharm Labs Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medipharm Labs Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Logic Instrume
PA:ALLOG
|
-0.125x |
|
Mirasol Resources Ltd
V:MRZ
|
0.915x |
|
Calgro M3 Holdings Ltd
JSE:CGR
|
-0.059x |
|
Longeveron LLC
NASDAQ:LGVN
|
-0.273x |
|
OYAK Yatirim Ortakligi AS
IS:OYAYO
|
-0.012x |
|
Four Seasons Education Cayman
NYSE:FEDU
|
N/A |
|
Allied Industrial Ltd
TWO:4702
|
-0.006x |
|
Helium Evolution Inc
V:HEVI
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Medipharm Labs Corp (2016–2025)
The table below shows the annual cash flow conversion efficiency of Medipharm Labs Corp from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Medipharm Labs Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$35.81 Million ≈ $25.91 Million |
CA$-5.50 Million ≈ $-3.98 Million |
-0.154x | -36.54% |
| 2024-12-31 | CA$43.18 Million ≈ $31.24 Million |
CA$-4.86 Million ≈ $-3.52 Million |
-0.113x | +51.65% |
| 2023-12-31 | CA$53.01 Million ≈ $38.34 Million |
CA$-12.34 Million ≈ $-8.93 Million |
-0.233x | +18.87% |
| 2022-12-31 | CA$56.01 Million ≈ $40.51 Million |
CA$-16.07 Million ≈ $-11.62 Million |
-0.287x | -80.55% |
| 2021-12-31 | CA$83.15 Million ≈ $60.15 Million |
CA$-13.21 Million ≈ $-9.56 Million |
-0.159x | +67.01% |
| 2020-12-31 | CA$78.41 Million ≈ $56.72 Million |
CA$-37.77 Million ≈ $-27.32 Million |
-0.482x | -150.20% |
| 2019-12-31 | CA$131.23 Million ≈ $94.93 Million |
CA$-25.27 Million ≈ $-18.28 Million |
-0.193x | +51.76% |
| 2018-12-31 | CA$27.84 Million ≈ $20.14 Million |
CA$-11.11 Million ≈ $-8.04 Million |
-0.399x | -410.70% |
| 2017-12-31 | CA$-2.12 Million ≈ $-1.54 Million |
CA$166.00K ≈ $120.08K |
-0.078x | +69.21% |
| 2016-12-31 | CA$215.46K ≈ $155.86K |
CA$-54.69K ≈ $-39.56K |
-0.254x | -- |
About Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It a… Read more